CO6721048A2 - Anticuerpos que se unen a notum pectinacetilesterasa - Google Patents

Anticuerpos que se unen a notum pectinacetilesterasa

Info

Publication number
CO6721048A2
CO6721048A2 CO13149527A CO13149527A CO6721048A2 CO 6721048 A2 CO6721048 A2 CO 6721048A2 CO 13149527 A CO13149527 A CO 13149527A CO 13149527 A CO13149527 A CO 13149527A CO 6721048 A2 CO6721048 A2 CO 6721048A2
Authority
CO
Colombia
Prior art keywords
antibodies
pectinacetilesterase
notum
bind
bind notum
Prior art date
Application number
CO13149527A
Other languages
English (en)
Spanish (es)
Inventor
Robert Joseph Brommage
Xiao Feng
Seokjoo Hong
Gregory M Landes
Jeff Liu
David Potter
David Reed Powell
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of CO6721048A2 publication Critical patent/CO6721048A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
CO13149527A 2010-11-24 2013-06-24 Anticuerpos que se unen a notum pectinacetilesterasa CO6721048A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41692710P 2010-11-24 2010-11-24

Publications (1)

Publication Number Publication Date
CO6721048A2 true CO6721048A2 (es) 2013-07-31

Family

ID=46146184

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13149527A CO6721048A2 (es) 2010-11-24 2013-06-24 Anticuerpos que se unen a notum pectinacetilesterasa

Country Status (21)

Country Link
US (3) US20130302346A1 (enExample)
EP (1) EP2643019B1 (enExample)
JP (1) JP6033229B2 (enExample)
KR (2) KR20180069083A (enExample)
CN (1) CN103298490B (enExample)
AU (1) AU2011332007C1 (enExample)
BR (1) BR112013012858B1 (enExample)
CA (1) CA2817415C (enExample)
CO (1) CO6721048A2 (enExample)
DK (1) DK2643019T3 (enExample)
ES (1) ES2718849T3 (enExample)
HU (1) HUE043576T2 (enExample)
IL (1) IL225876A0 (enExample)
MX (2) MX385858B (enExample)
NZ (1) NZ609501A (enExample)
PL (1) PL2643019T3 (enExample)
PT (1) PT2643019T (enExample)
RU (1) RU2013123793A (enExample)
SG (1) SG189982A1 (enExample)
WO (1) WO2012071381A1 (enExample)
ZA (1) ZA201302983B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004776A2 (pt) * 2010-08-27 2017-09-19 Stem Centrx Inc moduladores de proteína notum e métodos de uso
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
US8802365B2 (en) * 2011-03-22 2014-08-12 Whitehead Institute For Biomedical Research Methods for identifying candidate modulators of NOTUM activity
JP6391574B2 (ja) * 2012-08-31 2018-09-26 アルゲン−エックス ビーブイビーエー 種間標的内交差反応性を有する抗体分子を産生する方法
CA2976926A1 (en) 2015-02-19 2016-08-25 Compugen Ltd. Anti-pvrig antibodies and methods of use
WO2020150282A1 (en) * 2019-01-18 2020-07-23 Askgene Pharma Inc. Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
CN110317271B (zh) * 2019-07-02 2021-04-30 武汉云克隆科技股份有限公司 一种pinp重组抗体的重/轻链可变区及编码基因和重组抗体
AU2021400733A1 (en) * 2020-12-16 2023-07-13 Memorial Sloan Kettering Cancer Center Cd40 binding molecules and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6080576A (en) 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
GB0201808D0 (en) * 2002-01-25 2002-03-13 European Molecular Biology Lab Embl Protein
US20040063924A1 (en) * 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
EP1652923B1 (en) * 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
BR112013004776A2 (pt) * 2010-08-27 2017-09-19 Stem Centrx Inc moduladores de proteína notum e métodos de uso
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.

Also Published As

Publication number Publication date
ZA201302983B (en) 2017-06-28
EP2643019B1 (en) 2019-01-02
MX2013005906A (es) 2013-06-28
US20190241677A1 (en) 2019-08-08
MX357166B (es) 2018-06-28
DK2643019T3 (en) 2019-04-15
BR112013012858A2 (pt) 2018-09-04
CA2817415A1 (en) 2012-05-31
AU2011332007B2 (en) 2016-11-10
KR20140026334A (ko) 2014-03-05
AU2011332007A1 (en) 2013-05-09
WO2012071381A1 (en) 2012-05-31
JP2014501513A (ja) 2014-01-23
NZ609501A (en) 2014-12-24
MX385858B (es) 2025-03-18
BR112013012858B1 (pt) 2021-12-07
KR20180069083A (ko) 2018-06-22
RU2013123793A (ru) 2014-12-27
US20130302346A1 (en) 2013-11-14
EP2643019A1 (en) 2013-10-02
JP6033229B2 (ja) 2016-11-30
CA2817415C (en) 2020-05-12
SG189982A1 (en) 2013-06-28
ES2718849T3 (es) 2019-07-04
PT2643019T (pt) 2019-04-23
PL2643019T3 (pl) 2019-07-31
CN103298490B (zh) 2017-04-26
AU2011332007C1 (en) 2017-03-02
IL225876A0 (en) 2013-06-27
CN103298490A (zh) 2013-09-11
EP2643019A4 (en) 2014-12-31
HUE043576T2 (hu) 2019-08-28
US20160152731A1 (en) 2016-06-02
US11059907B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
CL2012003385A1 (es) Tratamiento para la incontinencia.
ECSP099502A (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
SV2010003593A (es) Nuevos herbicidas
UY34210A (es) Composiciones, métodos y sistemas para la micropropagación de plantas
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
ECSP14004976A (es) Anticuerpos anti-il-36r
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
UY33931A (es) Agentes de union biespecificos
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
MX374399B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
MX366296B (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
CR20150047A (es) Anticuerpos anti-cd22 e inmunoconjugados
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
AR090923A1 (es) Anticuerpos anti-il-23
NI201100208A (es) Pirazinilpirazoles
BR112013032876A2 (pt) uso de formulações, e, método para fertilizar plantas
BR112013007514A2 (pt) anticorpo isolado, uso da composição e método

Legal Events

Date Code Title Description
FA Application withdrawn